Business Segments · Income (Loss) from Equity Method Investments

Reportable Segment — Income (Loss) from Equity Method Investments

Amgen Reportable Segment — Income (Loss) from Equity Method Investments increased by 155.6% to $10.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 135.7%, from -$28.00M to $10.00M.

Analysis

StatementSegment
First reportedQ1 2024
Last reportedQ3 2025
Rolls up toEquity Method Income
Metric ID: amgn_segment_reportable_segment_income_loss_from_equity_method_investments

Historical Data

6 periods
 Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25
Value$27.00M$12.00M-$28.00M-$11.00M-$18.00M$10.00M
QoQ Change—-55.6%-333.3%+60.7%-63.6%+155.6%
YoY Change———-140.7%-250.0%+135.7%
Range-$28.00M – $27.00M
CAGR-54.8%
Avg YoY Growth-85.0%
Median YoY Growth-140.7%

Frequently Asked Questions

What is Amgen's reportable segment — income (loss) from equity method investments?
Amgen (AMGN) reported reportable segment — income (loss) from equity method investments of $10.00M in Q3 2025.
How has Amgen's reportable segment — income (loss) from equity method investments changed year-over-year?
Amgen's reportable segment — income (loss) from equity method investments increased by 135.7% year-over-year, from -$28.00M to $10.00M.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.